CD22 and leukemia: In 2019, Ramakrishna et al., demonstrated that inclusion of bryostatin augmented anti-CD22 CAR activity in murine model systems by increasing CD22 antigen expression on the ALL cell lines NALM6 and KOPN8, two model leukemia cell lines, as well as a patient derived xenograft, building on earlier work in chronic lymphocytic leukemia (CLL) (13, 14).